Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
3.510
-0.080 (-2.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session
May 15, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
May 11, 2023
Company-sponsored webinar to be announced
From
Editas Medicine, Inc.
Via
GlobeNewswire
6 Analysts Have This to Say About Editas Medicine
May 08, 2023
Via
Benzinga
Editas Medicine: Q1 Earnings Insights
May 05, 2023
Via
Benzinga
Editas Medicine Announces First Quarter 2023 Results and Business Updates
May 05, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Preview: Editas Medicine's Earnings
May 04, 2023
Via
Benzinga
2 Stocks Under $15 Per Share to Consider
April 16, 2023
Anyone can get in on the stock market at these prices.
Via
The Motley Fool
Editas Medicine Earnings Preview
February 21, 2023
Via
Benzinga
Earnings Scheduled For May 5, 2023
May 05, 2023
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.
Via
Benzinga
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
May 01, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
May 01, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
The 3 Most Promising Gene Editing Stocks to Buy in 2023
April 28, 2023
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.
Via
InvestorPlace
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
April 27, 2023
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end
From
Editas Medicine, Inc.
Via
GlobeNewswire
Why Shares of Editas Medicine Rose Monday
April 17, 2023
The company is benefiting from positive news affecting other gene-editing stocks.
Via
The Motley Fool
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.
Via
Benzinga
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
April 13, 2023
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks.
Via
InvestorPlace
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 13, 2023
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday.
Via
Benzinga
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
April 13, 2023
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
April 13, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Proceed With Caution When Considering These 5 Ultra-Popular Stocks
April 13, 2023
Four of these five stocks are losing money.
Via
The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
April 06, 2023
Neither stock is a good choice for those who can't handle a lot of risk.
Via
The Motley Fool
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?
April 03, 2023
EDIT-301 had positive clinical results in treating sickle cell disease, but the potential payoff is still years in the future.
Via
The Motley Fool
2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It
March 30, 2023
Editas Medicine is a high-risk stock with the potential of a big reward.
Via
The Motley Fool
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
March 29, 2023
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.
Via
InvestorPlace
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
March 25, 2023
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.
Via
InvestorPlace
Thinking of Buying Biotech Stocks? Do These 3 Things First
March 22, 2023
It's better to plan ahead than to get caught by surprise.
Via
The Motley Fool
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
March 08, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
February 22, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
These 2 Biotech Stocks Could Soar in the Next Bull Market
February 17, 2023
They're both at the cutting edge of gene-editing technology.
Via
The Motley Fool
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
February 16, 2023
Which of these rebounding biotech stocks is the better buy right now?
Via
The Motley Fool
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.